Full Press Release Details
IMMUTEP GRANTED UNITED STATES PATENT FOR EFTILAGIMOD ALPHA
IN CHEMO-IMMUNOTHERAPY COMBINATION
SYDNEY, AUSTRALIA 11 August 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the
Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 10,736,940) entitled Combined Preparations for the Treatment of
Cancer by the United States Patent Office.
This United States patent follows the grant of the corresponding European, Australian and Japanese
patents (announced 23 May 2019, 21 June 2019 and 7 May 2020, respectively) and protects Immutep s intellectual property relating to combined therapeutic preparations comprising its lead active immunotherapy candidate eftilagimod
alpha ( efti or IMP321 ) and a chemotherapy agent. The chemotherapy agent is either a platinum-based anti-neoplastic agent, such as oxaliplatin or carboplatin, or a topoisomerase I inhibitor, such as topotecan.
This new patent highlights the ongoing and important steps being taken by the Company to protect its lead product candidate in a range of novel and highly
relevant combination formats, in both chemo-immunotherapy and other immunotherapy settings.
The patent expiry date is 25 January 2035 (including 37
days of patent term adjustment).
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related
immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Immutep s current lead product
candidate is eftilagimod alpha ( efti or IMP321 ), a soluble LAG-3 protein (LAG-3Ig) based on the LAG-3
immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is currently in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov
identifier NCT02614833); a Phase II clinical trial being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) referred to as
TACTI-002 to evaluate a combination of efti with KEYTRUDA (pembrolizumab) in several different solid tumours (clinicaltrials.gov identifier
NCT03625323); a Phase I clinical trial being conducted in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. referred to as INSIGHT-004 to evaluate a combination of efti with avelumab (clinical
trials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT02676869).
Immutep Limited, Level
12, 95 Pitt Street, Sydney NSW 2000
Additional LAG-3 products, including antibodies, for immune response
modulation in autoimmunity and cancer are being developed by Immutep s large pharmaceutical partners. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.
Further information can be found on the Company s website www.immutep.com or by contacting:
Australian Investors/Media:
+61 (0)406 759 268; cstrong@citadelmagnus.com
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com
announcement was authorised for release by the board of Immutep Limited.
Immutep Limited, Level
12, 95 Pitt Street, Sydney NSW 2000